Back to search

Article

Pruritus Related to Trastuzumab and Pertuzumab in HER2+ Breast Cancer Patients

2023-04-28

Abstract excerpt

<title>Abstract</title> <p><bold>Purpose</bold> The combination of trastuzumab and pertuzumab (HP) as part of a taxane-based regimen has shown benefit in the adjuvant and metastatic HER2+ breast cancer setting. In the CLEOPATRA trial, pruritus was reported in 11-17.6% of patients. The clinical phenotype and potential treatment strategies for this event have not been reported. <bold>Methods</bold> A retrospective...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
950803de-8812-5fa1-adee-aa2e621c0a8b
DOI
10.21203/rs.3.rs-2679676/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Pruritus Related to Trastuzumab and Pertuzumab in HER2+ Breast Cancer PatientsDOI 10.21203/rs.3.rs-2679676/v1
Biologic Treatment for Cutaneous Immune-Related Adverse Events in Cancer Patients Undergoing Immune-Checkpoint Therapy: A Retrospective ReviewSemantic proximity
Long-term mortality outcomes among immunotherapy recipients treated with dupilumab for the management of cutaneous immune-related adverse eventsSemantic proximity
Treatment of Chronic Spontaneous Urticaria With Benralizumab: Report of Primary Endpoint Completer Analysis, Secondary and Exploratory EndpointsSemantic proximity
Therapeutic outcomes across Janus kinase inhibitors in prurigo nodularisSemantic proximity
Adverse event profile differences between Trastuzumab Emtansine and Trastuzumab Deruxtecan: a real-world, pharmacovigilance studySemantic proximity
Management of Hypersensitivity in Oncology Practice: Risk Stratification, Phenotypic Markers, and Desensitization ProtocolsSemantic proximity
Evaluation of Symptom and Side Effect Bother in Cutaneous T-cell Lymphoma Patients Treated with Mogamulizumab or VorinostatSemantic proximity
Cutaneous adverse events associated with Rybrevant based on FDA Adverse Event Reporting System (FAERS) database from 2021 to 2024Semantic proximity
Management of adverse reactions to biologic agents.Semantic proximity
Tralokinumab shows clinical improvement in patients with prurigo nodularis-like phenotype atopic dermatitis: A multicenter, prospective, open-label case series study.Semantic proximity
Skin Lesions in Patients Treated with BTK InhibitorsSemantic proximity
Interventions with Potential to Mitigate Injection Site Reactions Following Subcutaneous Elamipretide Administration: A Phase 1, Crossover StudySemantic proximity
Select a neighboring publication to make it the new centre.